Canakinumab News
Canakinumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Canakinumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:...
- Evidence level: L5
- Predicted indications (20):
- hepatic infarction (99.9%)
- hepatic veno-occlusive disease (99.8%)
- peliosis hepatis (99.8%)
- syndrome with combined immunodeficiency (99.7%)
- autosomal dominant familial periodic fever (99.7%)
- periodic fever-infantile enterocolitis-autoinflammatory syndrome (99.6%)
- autosomal recessive familial Mediterranean fever (99.5%)
- familial Mediterranean fever, autosomal dominant (99.4%)
- extracutaneous mastocytoma (99.3%)
- Blau syndrome (99.3%)
- monosomy X (99.3%)
- liver angiosarcoma (99.3%)
- aggressive systemic mastocytosis (99.3%)
- X-linked lymphoproliferative disease due to SH2D1A deficiency (99.3%)
- familial Mediterranean fever (99.2%)
- primary release disorder of platelets (99.2%)
- pseudo-von Willebrand disease (99.1%)
- hepatic veno-occlusive disease-immunodeficiency syndrome (99.1%)
- systemic mastocytosis (99.0%)
- chromhidrosis (99.0%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.